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IsoproterenolThe responses of AMP-activated protein kinase (AMPK) and Ornithine decarboxylase (ODC) to isoproterenol
have been examined in H9c2 cardiomyoblasts, AMPK represents the link between cell growth and energy
availability whereas ODC, the key enzyme in polyamine biosynthesis, is essential for all growth processes
and it is thought to have a role in the development of cardiac hypertrophy. Isoproterenol rapidly induced
ODC activity in H9c2 cardiomyoblasts by promoting the synthesis of the enzyme protein and this effect
was counteracted by inhibitors of the PI3K/Akt pathway. The increase in enzyme activity became signiﬁcant
between 15 and 30 min after the treatment. At the same time, isoproterenol stimulated the phosphorylation
of AMPKα catalytic subunits (Thr172), that was associated to an increase in acetyl coenzyme A carboxylase
(Ser72) phosphorylation. Downregulation of both α1 and α2 isoforms of the AMPK catalytic subunit by
siRNA to knockdown AMPK enzymatic activity, led to superinduction of ODC in isoproterenol-treated cardi-
omyoblasts. Downregulation of AMPKα increased ODC activity even in cells treated with other adrenergic ag-
onists and in control cells. Analogue results were obtained in SH-SY5Y neuroblastoma cells transfected with a
shRNA construct against AMPKα. In conclusion, isoproterenol quickly activates in H9c2 cardiomyoblasts two
events that seem to contrast one another. The ﬁrst one, an increase in ODC activity, is linked to cell growth,
whereas the second, AMPK activation, is a homeostatic mechanism that negatively modulates the ﬁrst. The
modulation of ODC activity by AMPK represents a mechanism that may contribute to control cell growth
processes.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Cardiac hypertrophy and the subsequent progression towards
heart failure represent a major cause of morbidity and mortality in in-
dustrialized countries. The deﬁning features of cardiac hypertrophy
are an increase in cardiomyocyte size, enhanced protein synthesis,
and a higher degree of sarcomere organization [1]. These changes
are preceded and accompanied by the re-induction of the so-called
fetal cardiac gene program, characterized by a pattern of altered
gene expression that mimics that observed during embryonic heart
development [2]. Cardiac hypertrophy is also associated with a shift
from fatty acids to glucose as the primary energy source, an additionalAMPK, AMP-Activated Protein
omethylornithine; ODC, Orni-
elli).
l rights reserved.feature in common with the fetal heart. A characteristic event in re-
sponse to agents that induce cardiac hypertrophy is the upregulation
of Ornithine decarboxylase (ODC), the key enzyme in the biosynthe-
sis of polyamines. Polyamines have multiple roles in cardiac physiol-
ogy [3] and a role for ODC and polyamine metabolism in cardiac
hypertrophy was described since long ago [4]. Virtually all treatments
that lead to cardiac hypertrophy cause an early induction of cardiac
ODC either in the whole animal [4,5] and in cellular models [6–8].
In the classical model of adrenergic agonist-induced hypertrophy,
pharmacological inhibition of ODC results in an attenuation of the hy-
pertrophic response [4–6,9], suggesting a role of ODC in this process.
More recently, targeted ODC overexpression in the heart was found to
produce a moderate baseline cardiac hypertrophy in transgenic mice
that also exhibited a greatly increased sensitivity to isoproterenol-
induced hypertrophy [9]. On the other hand, ODC inhibition did not
inﬂuence the expression of markers of hypertrophy in post-ischemic
hearts [10] or following tiroxine treatment [11].
Adenosine monophosphate (AMP)-activated protein kinase
(AMPK) is a key metabolic regulator that is activated in response to
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Additionally this enzyme can be activated by hormones that inﬂuence
cellular metabolism, such as adiponectin and catecholamines [12].
The role of AMPK in cardiac hypertrophy is complex, and apparently
contrasting ﬁndings are reported in literature. Many papers, reviewed
in Refs. [13,14], have shown that AMPK has an anti-hypertrophic role.
In this respect, strong evidence comes from the enhanced cardiac
hypertrophy in genetic models with diminished heart AMPK activity
[15,16] and from the fact that AMPK inhibits ATP consuming path-
ways such as protein synthesis [17]. On the other hand, activation
of AMPK in hypertrophied hearts has been observed in a number
of studies, reviewed in Refs. [14,18], and could be associated to the
energetic requirements of hypertrophic heart [19–21]. Furthermore,
adrenergic agonists cause an increase in AMPK activation in several
cells and tissues, including different cardiac models [22–25], even if
they are classical inducers of cardiac hypertrophy either in vivo or in
vitro. In this light, the typical ODC induction triggered by adrenergic
effector discussed above, seems to be in contrast with the well docu-
mented homeostatic role of AMPK that inhibits protein synthesis by
interfering with the mTOR pathway [17,26]. To date, nothing is
known about the possible interrelations between AMPK and ODC
and we have now examined the response of the two enzymes to ad-
renergic stimulation in H9c2 heart cells, that represent a useful
model in which molecular events associated to hypertrophy can be
studied [27].
2. Materials and methods
2.1. Cell culture and treatment
H9c2 cardiomyoblasts (embryonic rat-heart derived cells) were
cultured in Dulbecco's modiﬁed Eagle's medium (DMEM, Celbio)
supplemented with 10% heat inactivated fetal calf serum (FCS), 5%
glutamine and antibiotics as described [28]. Cardiomyocyte cultures
were prepared from 1- to 3-day old newborn Wistar rat hearts, as
described previously [8]. Before the treatments, the cells were
serum starved for 18 h in medium containing 1% FCS. SH-SY5Y neu-
roblastoma cells were cultured in HAM'S F-12 / MEM containing 10%
fetal bovine serum, 5% glutamine, 1% non-essential amino acids and
antibiotics.
All treatments were dissolved in phosphate-buffered saline (PBS)
or dimethylsulphoxide (DMSO) at 1000× concentration and added to
cell cultures in order to obtain the required concentration in the me-
dium. Control cells received the corresponding volume of the vehicle.
Cell viability was determined by trypan blue exclusion by counting
living cells and stained dead cells with a Burker hemocytometer.
2.2. Western blotting
H9c2 cells were collected in lysis buffer (5 mM dithiothreitol,
2 mM EDTA, 0.1% CHAPS, 0.1% Triton X-100, and protease inhibitors
in 20 mM HEPES pH 7.5) and subjected to two cycles of freeze-
thawing. The homogenate was then centrifuged at 15,000 ×g for
15 min and the supernatant, diluted in loading buffer (2% SDS,
5% glycerol, 0.002% bromophenol blue, 4% β-mercaptoethanol in
0.25 M Tris–HCl, pH 6.8), and then denatured by boiling for 4 min.
Aliquots corresponding to 80 μg protein were analyzed by SDS-
PAGE. Proteins were transferred onto a nitrocellulose membrane
and probed with the speciﬁc primary antibody. After further washing,
the membrane was then incubated for 1 h with peroxidase-
conjugated goat anti-rabbit IgG (Santa Cruz). Immunoreactive bands
were visualized by chemiluminescence with the ECL reagent (Amer-
sham). Antibodies against phospho-Acetyl Coenzyme A Carboxylase
β (ACC) (Ser79 in human), AMPKα1/α2, phospho-AMPKα1/α2
(Thr172 in human), phospho-Akt (Ser473) were from Cell Signaling.
Anti-Akt, anti-ACC, anti-GAPDH, and anti-β-actin were obtainedfrom Santa Cruz. β-Actin or GAPDH was used as internal control.
Quantitative assay of immunoblotting was obtained by densitometry
with a Fluor-S Max MultiImager instrument (Bio-Rad).
2.3. ODC activity and expression
To measure the activity of ODC, the cells were washed with PBS
and scraped in a buffer consisting of 0.1 mM EDTA, 0.02 mM pyri-
doxal phosphate, 1% Triton X-100, 5 mM dithiothreitol in 50 mM
Tris-HCl buffer, pH 7.2. The cells were disrupted by freeze-thawing
three times and then centrifuged at 11,000 rpm for 15 min. ODC ac-
tivity in the supernatant was measured in duplicate by estimating
the release of 14CO2 from [14C-Carboxyl]-ornithine during a 60 min
incubation [28]. Speciﬁc ODC activity is expressed as units/mg pro-
tein, where 1 unit corresponds to 1 pmol of CO2/min of incubation.
The amount of protein in samples was determined by the Bradford
method [29]. The level of ODC mRNA was measured by using real-
time PCR. β-Actin was used as a housekeeping gene. Sample extrac-
tion and PCR details [25], and primers used in PCR [30] were previ-
ously described.
2.4. Cell metabolites
Acid-soluble metabolites were extracted in ice cold 0, 3 M per-
chloric acid and measured by HPLC. Separations were achieved by a
25 cm×4.6 mm Gemini 5μ column from Phenomenex. Polyamines
in cardiac cells were determined in acidic cellular extracts by reversed
phase HPLC after derivatization with dansyl chloride [31]. The cellular
content of ATP and other nucleotides was determined after extract
neutralization with buffered 3 M KOH following conversion into ﬂuo-
rescent etheno-derivatives [32].
2.5. RNA interference
The sequences of short interfering RNAs (siRNA) directed against
the catalytic subunits of rat AMPK (Obtained from Sigma-Genosys)
were as follows: for AMPKα1, 5′-CUUAUUGGAUUUCCGAAGUTT-3′;
for AMPKα2, 5′-GACAUUAUGGCGGAGGUGUTT-3′. In most experi-
ments, a siRNA against Luciferase (Luc) was used as negative control
(5′-AACUUACGCUGAGUACUUCTT-3′). In some cases, the control
siRNA-A, purchased from Santa Cruz Biotechnology, was used. For
transient transfection experiments, H9c2 cells at 50% of conﬂuence
were transfected with a ﬁnal concentration of 100 nM siRNA for
24 h by Transfection reagent (Santa Cruz) according to manufac-
turer's instructions. Transfection in newborn rat cardiomyocytes
was achieved as described [25]. Twenty-four hours after transfection,
cells were then treated with the designated drugs. RNA interference
by short hairpin RNA (shRNA) was obtained with constructs pur-
chased from Sigma-Aldrich (MISSION® shRNA). SH-SY5Y cells were
transfected with either a control shRNA or shRNA against the expres-
sion of AMPKα1 using the FuGene reagent (Roche) and subject to pu-
romycin selection.
2.6. Hypertrophy experiments
The rate of protein synthesis in H9c2 cells was measured by [3H]
leucine incorporation in acid-insoluble fraction [33]. The protein
content per cell was assayed as described by Hwang et al. [34]. The
expression of the hypertrophy marker ANF was determined by
real-time PCR as previously detailed [8], β-actin being used as
housekeeping gene.
2.7. Data analysis
All the experiments shownwere performed independently at least
three times with comparable results. The blots are representative of
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graphs are expressed as means±S.E. of the mean of the indicated
numbers of independent determinations. Statistical comparison be-
tween two groups was done by Student's unpaired two-tailed t test
or one-way ANOVA analysis, when appropriate. Differences were
considered as signiﬁcant when Pb0.05.
3. Results
Adrenergic agonists such as phenylephrine and isoproterenol
cause a hypertrophic response in H9c2 cardiomyoblasts similar to
that evoked in primary cardiomyocytes and in the whole heart
[33–35]. The effect of isoproterenol on AMPK activation was ﬁrstly
studied. Analysis of soluble extracts prepared from whole H9c2 cell
lysates showed increased AMPKα (Thr172) phosphorylation follow-
ing treatment with isoproterenol (10 μM). The experiment depicted
in Fig. 1A shows that an increased phosphorylation of AMPKα cata-
lytic subunits could be observed as soon as 15 min. This effect
remained detectable for 2–3 h and was accompanied with the in-
creased phosphorylation of its substrate ACC (Ser79). After 30 min
of isoproterenol treatment, the AMPK phosphorylation level was in-
creased by 1.9±0.4 times with respect to control cells (n=6,
Pb0.05), and that of ACC by 1.7±0.2 times (n=3, Pb0.05). AMPK
phosphorylation was also increased (Fig. 1B) by phenylephrine and
by the physiological effector norepinephrine (both 10 μM), according
to previous reports [23,36]. Pretreatment with the β-antagonist pro-
pranolol (10 μM) partially reduced AMPK phosphorylation in re-
sponse to isoproterenol (Fig. 1C). A strong increase in AMPKα
(Thr172) phosphorylation could be observed in cells incubated with
oligomycin plus deoxyglucose and was associated with a sharp in-
crease in the AMP/ATP ratio (Fig. 1D). The use of deoxyglucose was
required because, in our hands, hypoxia or mitochondrial inhibitors
alone scarcely affected adenylate nucleotide levels within 3 h, possi-
bly as a consequence of the dependence of H9c2 cells on anaerobic
glycolysis in these conditions, as evidenced by lactate accumulation
in the medium. On the other hand, the effect of isoproterenol was
not associated to any change in the level of ATP, ADP and AMP, and
the AMP/ATP ratio was unchanged.
Treatment with isoproterenol increased ODC activity with a
timing identical to that observed in rat cardiomyocytes [6] and inP-AMPK
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Fig. 1. Isoproterenol (ISO) increases AMPK phosphorylation in H9c2 cardiomyoblasts. (A) T
Cell lysates were analyzed by Western blotting with antibodies against α subunits of AMPK
(Ser79). (B) The cells were incubated for 1 h in the absence or presence of a 10 μM concentra
were analyzed byWestern blotting. (C) The phosphorylation of AMPKαwas assayed in cells
with 10 μM propranolol. (D) The cardiomyoblasts were incubated 60 min in the presence o
ward cells were collected for the determination of adenylate nucleotide levels and AMPKα p
measurements; *, Pb0.05 vs. control cells.the whole heart [4]. The increase in enzyme activity was very
rapid and became signiﬁcant between 15 and 30 min after the treat-
ment (Fig. 2A). After 4 h of treatment, putrescine, the product of
ODC catalysis, was increased (Fig. 2B), whereas the major poly-
amines spermidine and spermine were unchanged (not shown).
The increase in ODC activity was blocked by cycloheximide, an
inhibitor of protein synthesis (Fig. 2C). ODC is a short-lived protein,
whose level can be regulated by the rate of its degradation by the
proteasome [37]. In the presence of the proteasome inhibitor
MG132, basal ODC activity was increased as expected, however, iso-
proterenol continued to increase ODC activity (Fig. 2D), indicating
that a change in protein stability was not the primary mechanism
of ODC upregulation by isoproterenol. These data show that isopro-
terenol induced ODC activity by increasing the synthesis of new en-
zyme protein. Actually, the amount of ODC mRNA progressively
increased after 1 h and 2 h following isoproterenol (Fig. 2E). ODC in-
duction was blocked by propranolol (Fig. 2F).
ODC induction by isoproterenol was abolished in cells treated
with the PI3K/Akt pathway inhibitors Wortmannin and LY294002 or
with the dual PI3K/mTOR inhibitor BEZ235 (Fig. 3A). These inhibitors
also signiﬁcantly decreased the ODC basal activity in control cells,
suggesting a central role of Akt-mediated signalling in the regulation
of ODC. Akt (Ser473) phosphorylation was slightly but signiﬁcantly
increased following isoproterenol and after 30 min was increased
1.7±0.2 (n=4) times (Fig. 3B).
In isoproterenol-treated cells, inhibition of ODC activity by pre-
treatment with the irreversible and speciﬁc ODC inhibitor α-
diﬂuoromethylornithine (DFMO) (Fig. 4A) reduced the expression
of the hypertrophy related gene ANF (Fig. 4B) and prevented the in-
crease in [3H]leucine incorporation into cellular proteins (Fig. 4C)
and in the total protein content per cell (Fig. 4D). These data show
that ODC activity is required because H9C2 cells exposed to isoproter-
enol exhibit the characteristics of hypertrophy.
To determine whether ODC activity could be inﬂuenced by AMPK,
H9c2 cardiomyoblasts were exposed for 2 h to isoproterenol in the
presence of AMPK inhibitors AraA [38], compound C [39] or STO-
609 (Table 1). This last compound is a CAMKKβ inhibitor that in
some cases can prevent AMPK activation, since CAMKKβ is an AMPK
upstream kinase [12], but it has been proven to be also a powerful di-
rect inhibitor of AMPK [40]. Compound C could be used only atC D
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Fig. 2. Isoproterenol (10 μM, ISO) increases ODC activity and mRNA level in H9c2 car-
diomyoblasts. (A) The cells were incubated in the absence or presence of isoproterenol
for the indicated time. Cell lysates were then assayed for ODC activity. (B) The content
of putrescine was measured by HPLC in acid extracts from cells incubated for 4 h in the
absence or presence of isoproterenol. (C) H9c2 cells were treated with isoproterenol in
the absence or presence of 0.2 mM cycloheximide (Chx) to inhibit protein synthesis.
The cells were collected at the indicated time for the assay of ODC activity. (D) Control
cells and isoproterenol-treated cells were incubated 2 h in the absence of presence of a
10 μM concentration of the proteasome inhibitor MG132. The cells were then collected
and ODC was assayed in cell extracts. (E) ODC mRNA levels were measured at the in-
dicated time after isoproterenol treatment by real-time PCR. (F) ODC activity was
assayed in cells incubated 30 min with 10 μM isoproterenol with or without a pre-
treatment for 30 min with 10 μM propranolol. In all panels the presented results are
means±S.E. of three to ﬁve measurements. *, Pb0.05 vs. control cells.
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Fig. 3. Evidence that ODC activity in isoproterenol-treated cardiomyoblasts is regulated
by signaling through Akt. (A) ODC activity was measured in extracts from H9c2 cardi-
omyoblasts incubated 2 h in the absence or presence of 10 μM isoproterenol (ISO) and
the indicated compounds (2 μMwortmannin, 20 μM LY29004, 0.2 μM BEZ235). Results
are means±S.E. of three determinations. In isoproterenol treated cells: *, Pb0.05 vs.
cells incubated with isoproterenol only. In control cells: °, Pb0.05 vs. cells incubated
without any treatment. (B) The cells were incubated in the presence of 10 μM isopro-
terenol for the indicated time. Cell lysates were analyzed by Western blotting. The
blots are representative of multiple experiments.
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duced apoptosis. Interestingly, ODC activity resulted slightly in-
creased in cells incubated in the presence of aforementioned AMPK
inhibitors. On the other hand, the AMPK activator AICAR (4 mM)
and especially metformin (5 mM) slightly decreased ODC activity.
Phenformin, a more potent analogue of metformin, caused a dose de-
pendent inhibition of ODC activity. These results suggest that AMPK
activity could be associated to a decrease in ODC activity. On the con-
trary, ODC inhibition with 0.1 mM DFMO did not induce any effect on
AMPK level or phosphorylation in either control cells and
isoproterenol-treated cells (not shown).
Since the speciﬁcity of pharmacological inhibitors/activators al-
ways remains limited, to support the suggestion of a modulating ef-
fect of AMPK on ODC, a siRNA approach was used. The cells were
transfected with two siRNAs respectively targeted against the α1
and α2 isoforms of the AMPK catalytic subunit in order to knockdownAMPK enzymatic activity, or with a siRNA directed against luciferase
(control siRNA). The cardiac myoblasts were then exposed for 2 h to
isoproterenol. Fig. 5A shows that a signiﬁcant degree of reduction in
AMPKα protein level of about 70% was obtained in cells pretreated
with both siRNAs against α1 and α2 isoforms of AMPKα. This treat-
ment also led to a signiﬁcant reduction in cellular AMPK activity as
shown by the decrease in the phosphorylation of ACC (Ser79), a phys-
iological AMPK substrate. The knock-down of only one isoform of
AMPKα did not inﬂuence ACC (Ser79) phosphorylation.
When both α1 and α2 isoforms of AMPK were silenced, along
with the decrement in AMPK activity there was a marked increase
in ODC activity in H9c2 cells treated with isoproterenol. siRNA-
mediated downregulation of a single isoform had a very weak effect
on ODC activity, but the effect of the siRNA against α2 isoform was
somewhat more pronounced than that of the α1 siRNA. Fig. 5B
shows that the pretreatment with α1 plus α2 siRNAs increased ODC
activity also in response to adrenergic effectors norepinephrine or
phenylephrine. AMPK downregulation increased ODC activity in con-
trol cells too. The treatment with α1 plus α2 siRNAs did not inﬂuence
the expression of ERK 1/2 or Akt (not shown), that are associated to
the growth promoting effect of adrenergic stimulation in cardiac
cells [41,42].
Adrenergic agonists activate AMPK in several cardiac models and
norepinephrine increases AMPKα (Thr172) phosphorylation in neo-
natal rat cardiomyocytes [25]. With the aim to conﬁrm the modulat-
ing effect of AMPK on ODC in this somewhat more physiological
model, cardiomyocytes were transfected with AMPK α1 plus α2 siR-
NAs before the exposure to the adrenergic effector (Fig. 6A and B). In
primary cardiomyocytes the transfection efﬁciency was lower with
respect to H9c2 cardiomyoblasts and AMPKα was decreased by
42±7% (N=4). Nevertheless, after AMPK downregulation also in
rat cardiomyocytes it was possible to observe either the ODC super-
induction in response to norepinephrine and the increased basal
activity in control cells, even if this late difference did not reach the
level of signiﬁcance (P=0.078).
Fig. 4. Effect of ODC inhibition by DFMO on the development of hypertrophy in
isoproterenol-treated H9c2 cardiomyoblasts. After seeding, H9c2 cells were pre-
incubated in the absence or in the presence of 0.1 mM DFMO for 16 h. Then cells
were treated with 10 μM isoproterenol (ISO). (A) ODC activity was determined
after 2 h. (B) The expression of the hypertrophy marker ANF was assayed after 24 h
by real time PCR and normalized against β-actin. (C) To determine the rate of protein
synthesis, the cells were incubated for 24 h after isoproterenol in the presence of
[3H]leucine. (D) Total protein content per cell was measured after 48 h from isoproter-
enol. Results are means±S.E. of three determinations. *, Pb0.05 vs. cells incubated
with isoproterenol only.
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Fig. 5. AMPK knockdown causes an increase in ODC activity in isoproterenol-treated
H9c2 cardiomyoblasts. (A) The cells were transfected with a control siRNA against
luciferase (Luc), or AMPKα1 plus AMPKα2 siRNAs, or AMPKα1 siRNA, or AMPKα2
siRNA. The cells were then incubated in the absence or presence of 10 μM isoprotere-
nol. The amount of AMPKα and phospho-ACC was determined after 1 h, whereas ODC
activity was measured after 2 h of isoproterenol treatment. Results of ODC activity are
means±S.E. of three determinations, whereas the blots are representative of three
experiments. *, Pb0.05 vs. untransfected cells incubated with the same treatment.
(B) H9c2 cells transfected with the luciferase siRNA (Luc) or AMPKα1 plus AMPKα2
siRNAs, were incubated for 2 h in the absence or presence of 10 μM norepinephrine
(NE), or isoproterenol (ISO), or phenylephrine (PE), then ODC activity was measured
in cell extracts. Results are means±S.E. of three to ﬁve determinations. *, Pb0.05 vs.
untransfected cells incubated with the same treatment.
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port, we wanted to assess whether the modulatory effect of AMPK on
ODC activity was a characteristic of cellular models associated to hy-
pertrophic growth or was a more general mechanism. In these exper-
iments, AMPK downregulation by RNA interference was achieved
with a different technique in a different cell line. SH-SY5Y humanTable 1
Effect of pharmacological AMPK inhibitors/activators on ODC activity in untreated and
isoproterenol-treated H9c2 cardiomyoblasts.
Addition Effect on
AMPK
ODC activity (U/mg)
Ctrl ISO
None (ctrl) – 13±3 34±5
STO 609 (1 μM) Inhibitor 16±3 40±4
AraA (0.5 mM) Inhibitor 16±2 41±5
Compound C (1 μM) Inhibitor 13±2 37±3
AICAR (4 mM) Activator 11±3 29±4
Metphormin (5 mM) Activator 9±2* 23±4*
Phenformin (0.5 mM) Activator 12±2 30±4
Phenformin (1 mM) Activator 9±2* 26±3*
Phenformin (2 mM) Activator 8±1* 21±3*
ODC activity was determined in extracts from cells incubated 2 h in the absence or
presence of 10 μM isoproterenol (ISO) and the indicated compounds. Results are
means±S.E. of three to six determinations. In isoproterenol treated cells: *, Pb0.05
vs. cells incubated with isoproterenol only. In control cells: *, Pb0.05 vs. cells
incubated without any treatment.neuroblastoma cells were transfected with shRNA construct against
AMPKα1, that represents by far the major AMPKα isoform in this
cell line [43] and were then treated with isoproterenol. Again, the in-
crease in ODC activity was higher in cells with a lower level of AMPK
(Fig. 7). Also the basal ODC activity was signiﬁcantly higher when
AMPKα was knocked down. A similar response of basal ODC had
been observed also in H9c2 cells and rat cardiomyocytes (see
Figs. 5B and 6A) but in neuroblastoma cells appeared more
pronounced.
4. Discussion
AMPK, which is allosterically activated by AMP and phosphorylat-
ed by upstream kinases, represents a link between cell growth and
energy availability [12–14]. It is generally assumed that AMPK acti-
vates mechanisms that favour the formation of ATP both directly
and indirectly, and blocks mechanism that consume ATP, such as pro-
tein synthesis [17]. Because of its homeostatic role, AMPK could es-
sentially contrast the hyperplastic as well as hypertrophic growth
[44]. The role of AMPK in cardiac hypertrophy however is not fully
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Fig. 6. AMPK knockdown causes an increase in ODC activity in norepinephrine-treated
cardiomyocytes. (A) Neonatal rat cardiomyocytes were transfected with a control
siRNA against luciferase (Luc), or with AMPKα1 plus AMPKα2 siRNAs. The cells
were then incubated 2 h in the absence or presence of 10 μM norepinephrine (NE),
afterward ODC activity was assayed. Results are means±S.E. of three determinations.
*, Pb0.05 vs. untransfected cells incubated with the same treatment. (B) The amount
of AMPKα was determined in the same experiment of panel A after 1 h of norepi-
nephrine treatment. The blots are representative of three experiments.
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Fig. 7. AMPK downregulation by shRNA increases ODC activity in SH-SY5Y neurobla-
soma cells. The cells were transfected with constructs producing control shRNA or a
shRNA inhibiting AMPKα1 expression (AMPK shRNA). The blot shows the level of
AMPK in untransfected and transfected cells. The lower panel shows the effect of treat-
ment with 10 μM isoproterenol (ISO) for 2 h on ODC activity. Results are means±S.E.
of three determinations. *, Pb0.05 vs. untransfected cells incubated with the same
treatment.
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related events, by examining the responses of AMPK and ODC in a
cell model of induced hypertrophy. Our ﬁndings have shown that
treatment with adrenergic effectors such as isoproterenol quickly ac-
tivates in H9c2 cardiomyoblasts two mechanisms that seem to con-
trast one another. The ﬁrst one, increase in ODC activity, is linked to
cell growth, whereas the second, AMPK activation, is a homeostatic
mechanism that negatively modulates the ﬁrst.
Isoproterenol reportedly causes AMPK activation in 3 T3-L1 prea-
dipocytes [45], in brown adipocytes [46], in the pectoralis muscle of
chick [47], in rat heart [22], in neonatal rabbit heart [24]. In H9c2
cells, Xu et al. [23] did not see a signiﬁcant effect of isoproterenol
within 10 min, but we have observed that the increase in AMPKα
(Thr172) phosphorylation becomes well evident after 15–30 min of
treatment and is associated to increased enzyme activity, as shown
by the elevation in ACC phosphorylation. Boone et al. [48] have
shown that at very early times (2–3 min) after isoproterenol, protein
kinase A (PKA) has a role more pronounced than AMPK in the in-
crease in ACC phosphorylation. However, the downregulation of
AMPK by siRNA causes a signiﬁcant decrease in ACC (Ser79) phos-
phorylation after 30–60 min of exposure to isoproterenol, suggesting
that at these times AMPK is the main ACC kinase. Isoproterenol does
not increase the AMP/ATP ratio, but it is known that AMPK can be ac-
tivated by several alternative pathways; for example, AMPK (Thr172)
phosphorylation can increase in response to calcium or reactive oxy-
gen species [12]. Adrenergic stimulation activates AMPK in many cell
types with mechanisms that may be very complex [49] independent-
ly of the effect on cell growth, but possibly to prepare the cells for in-
creased energetic requirements [19,20]. According with this view,
and only apparently in contrast with other reports, recently it has
been published that adrenergic signaling can inactivate AMPK in
adult not-beating quiescent rat cardiomyocytes [50] in which, aspointed by the authors, the signaling pathways are very different
than those in contracting cardiomyocytes.
ODC is the enzyme responsible for the biosynthesis of putrescine,
the precursor of aliphatic polyamines [37]. Polyamines are critical in
the cell cycle, showing a marked increase during all cellular growth
processes [51]. Isoproterenol induces ODC activity in H9c2 cells by in-
creasing the level of ODC mRNA and ultimately promoting the syn-
thesis of the enzyme protein. ODC is one of the most ﬁnely
regulated enzymes [37] and its cellular activity results from the inte-
gration of many signals. ODC synthesis can be modulated by the PI3K/
Akt pathway and downstream by the mTOR/P70S6K axis [52–54], and
these pathways are known to be activated by isoproterenol in cardio-
myocytes [55–57]. In H9c2 cells, Jeong et al. did not observe change in
Akt phosphorylation 48 h after isoproterenol, when morphological
aspects of hypertrophy were established [35], but Yano et al. reported
a rapid activation within minutes [57]. In our experiments, isoproter-
enol causes a rapid increase in Akt phosphorylation, according to pre-
vious reports [56,57], that is associated to ODC induction.
Pharmacological inhibition of the PI3K/Akt pathway blocks ODC in-
duction by isoproterenol and also reduces the basal ODC activity in
control cells (Fig. 3), underlining the importance of Akt-mediated sig-
naling in ODC regulation. Inhibition of mTOR is an important aspect of
AMPK function [26] and it is thought to represent the main mecha-
nism of the anti-hypertrophic effect of AMPK [12,17]. So it seems rea-
sonable to think that this is probably also the mechanism responsible
of the negative modulation of ODC. AMPK downregulation increases
ODC induction by isoproterenol even in rat cardiomyocytes. Impor-
tantly, also basal ODC activity results higher when AMPK activity is
decreased, either in heart-derived cells as well as in unrelated neuro-
blastoma cells, suggesting a wide involvement of AMPK in ODC mod-
ulation. Actually, the basal degree of AMPKα (Thr172) and ACC
(Ser79) phosphorylation in control cells indicates a constitutive
basal level of AMPK activity that can be involved in the regulation of
cellular processes.
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trophy [3–9], and we have shown that ODC inhibition counteracts
the development of hypertrophic phenotype in isoproterenol-treated
H9c2 cardiomyoblasts. An obvious question is whether the modulatory
effect of AMPK on ODC represents a mechanism that can contribute to
control the developing of hypertrophy. Interestingly, in AMPKα2
knockout mice, p70S6K is constitutively overstimulated and the mice
develop an exaggerated myocardial hypertrophic response to isopro-
terenol [16], similar to that observed in mice with targeted overex-
pression of ODC in the heart [9]. However, as a cautionary note, it
should be noted that the precise role of ODC in cardiac hypertrophy
is not completely deﬁned; hence further work is required to answer
the question. In this respect it would be of interest to determine
ODC activity and expression in the heart of AMPK knockout mice.
Another question is why two apparently contrasting mechanisms
are activated at the same time in heart cells committed to hypertro-
phy. We think that the rapid activation of AMPK following adrenergic
stimuli is probably due to the cells effort to guarantee itself energetic
substrates in order to respond to an increase in ATP demand. The lack
of optimal nutritional conditions (energetic stress) leading to a pro-
longed activation of AMPK could instead contrast the establishment
of hypertrophy, possibly also by means of the negative modulation
of ODC. We have observed that AMPK downregulation affects ODC ac-
tivity even in neuroblastoma cells that obviously are not associated to
hypertrophic growth. Therefore, more in general, the ODC regulatory
action of AMPK may be one of the mechanisms by which cells couple
the control of cell growth with nutrients availability. In conclusion,
we suggest that the modulation of ODC activity by AMPK represents
a self-regulatory mechanism that can participate to the regulation of
cell growth processes.
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